Multiple Myeloma Treatment in India: Stem Cell Transplant, Costs & Options 2026
Multiple Myeloma Treatment in India: Stem Cell Transplant, Costs & Options 2026
Multiple myeloma is a cancer of plasma cells in the bone marrow. It is the most common haematological malignancy requiring stem cell transplantation in adults, and its treatment landscape has transformed dramatically in the past decade with new drug combinations and cellular therapies.
For African patients diagnosed with myeloma, India offers specialist haematology-oncology care — including autologous stem cell transplantation, VRd and DaraVRd induction protocols, and now CAR-T eligible programmes — at costs that make potentially curative or disease-controlling treatment accessible.
Understanding Multiple Myeloma: Key Facts
Myeloma accounts for 10% of all blood cancers. Median age at diagnosis is 65, but the disease occurs in younger patients too. It is characterised by:
- Overproduction of abnormal plasma cells in bone marrow
- Excess monoclonal immunoglobulin (paraprotein) in blood or urine
- Bone destruction, anaemia, renal impairment, hypercalcaemia
Symptoms that may prompt investigation: persistent bone pain (especially back and ribs), unexplained anaemia, recurrent infections, fatigue, elevated protein on routine blood tests.
Treatment Roadmap for Newly Diagnosed Myeloma
Treatment strategy depends on whether the patient is eligible for autologous stem cell transplant (ASCT):
Transplant-Eligible Patients (typically <70 years, fit)
Step 1: Induction chemotherapy (3–4 cycles)
Standard regimen in India: VRd (Bortezomib + Lenalidomide + Dexamethasone) or DaraVRd for eligible patients. Goal: maximum disease response before stem cell collection.
Step 2: Stem cell mobilisation and collection
G-CSF injections stimulate stem cell release from marrow into blood. Stem cells are harvested via apheresis (3–4 hour outpatient procedure). Usually sufficient cells for 1–2 future transplants are collected.
Step 3: High-dose melphalan conditioning
High-dose chemotherapy destroys remaining myeloma cells and the patient's bone marrow.
Step 4: Autologous stem cell infusion (ASCT)
The patient's own stored stem cells are re-infused. Engraftment (blood count recovery) takes 10–14 days in a protected BMT unit.
Step 5: Maintenance therapy
Lenalidomide maintenance post-transplant extends progression-free survival significantly. Duration typically 2 years or until progression.
Costs in India vs Other Countries
| Treatment Component | India (USD) | USA (USD) | UK Private (USD) |
|---|---|---|---|
| VRd induction (per cycle) | 2,000–4,000 | 15,000–25,000 | 12,000–20,000 |
| Stem cell mobilisation + collection | 2,500–4,000 | 25,000–40,000 | 20,000–35,000 |
| ASCT (conditioning + transplant + 30 days) | 18,000–25,000 | 120,000–200,000 | 80,000–150,000 |
| Lenalidomide maintenance (monthly) | 300–600 | 15,000–20,000 | 4,000–8,000 |
Indian generic lenalidomide (Lenalid) and bortezomib (Bortecad) — manufactured under compulsory licence — are clinically equivalent to branded Revlimid and Velcade at 5–15% of the branded price.
DaraVRd: The New Standard for Transplant-Eligible Patients
Daratumumab (Darzalex) combined with VRd (DaraVRd) is now the preferred induction regimen for transplant-eligible newly diagnosed myeloma following the GRIFFIN and PERSEUS trials. Results:
- Deeper responses (higher MRD-negative rates)
- Longer progression-free survival vs VRd alone
- Available in India: daratumumab biosimilar (Darzalas) available at major centres
DaraVRd induction (4 cycles) costs approximately USD 10,000–18,000 at Indian hospitals — compared to USD 80,000–120,000 in the USA.
New Drug Options Available in India
| Drug | Indication | India Availability | India Cost vs USA |
|---|---|---|---|
| Daratumumab (subcutaneous) | Induction, maintenance, relapse | Yes (biosimilar) | ~80% cheaper |
| Carfilzomib (Kyprolis) | Relapsed/refractory | Yes | ~60–70% cheaper |
| Pomalidomide | Relapsed/refractory | Yes (generic Pomalid) | ~85% cheaper |
| Isatuximab (Sarclisa) | Relapsed/refractory | Select centres | ~50% cheaper |
| NexCAR19 (CAR-T) | Relapsed/refractory B-cell | Tata Memorial, Apollo | ~90% cheaper than USA |
Leading Hospitals for Myeloma in India
Tata Memorial Hospital, Mumbai
India's national cancer centre. The haematology department manages the highest myeloma case volume in India. Costs are the lowest of any accredited centre. International patient services are available, though waiting times can be longer.
Apollo Cancer Centre, Delhi and Chennai
Full myeloma programme including DaraVRd, ASCT, and maintenance. Excellent international patient facilities, shorter waiting times.
Fortis Memorial Research Institute, Gurgaon
Strong BMT unit with experienced haematologists. High international patient volume from African countries.
Christian Medical College, Vellore
Academic excellence, experienced haematology team, affordable costs. Strong nursing care standards.
What to Bring: Medical Records for Myeloma Assessment
Before travelling to India, gather:
- Serum protein electrophoresis (SPEP) and immunofixation reports
- 24-hour urine protein electrophoresis
- Serum free light chain assay
- Bone marrow biopsy report (with cytogenetics/FISH if available)
- Full blood count, renal function, LFT, calcium, LDH
- Skeletal survey or PET-CT/whole body MRI if done
- Previous treatment records (if relapsed)
Treatment Timeline Planning
For transplant-eligible patients completing full induction + ASCT in India:
| Phase | Duration | Location |
|---|---|---|
| Initial assessment | 5–7 days | India |
| Induction chemotherapy | 4–6 months | Some cycles possible at home |
| Stem cell collection | 1 week | India |
| ASCT + engraftment | 4–6 weeks | India (BMT unit admission) |
| Recovery post-ASCT | 2–4 weeks | India or return home |
| Maintenance | Months–years | At home with remote monitoring |
Arodya helps structure which phases can occur in India versus at home, minimising total travel time and cost.
Starting Your Myeloma Treatment Journey
Multiple myeloma treatment in India is among the most compelling cost-quality propositions in global medical tourism. The same drugs, the same protocols, and experienced haematologists — at prices 70–90% lower than Western equivalents.
Share your reports with Arodya and get a free specialist review →
We'll send your case summary to a senior haematologist, provide a detailed treatment plan and cost breakdown, and coordinate the full journey from first consultation to discharge.
